Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer.
Savannah S LiddellSakti ChakrabartiGrant A WintheiserTyler J ZemlaQian ShiSri Harsha TellaZhaohui JinVanessa B WookeyHind HassanNguyen H TranMitesh J BoradAmit MahipalPublished in: JCO precision oncology (2022)
ICIs are well tolerated and have modest antitumor activity in patients with advanced BTC. The study result supports the exploration of tumor mutational burden as a potential predictive biomarker for response to ICIs in patients with advanced BTC.